<DOC>
	<DOCNO>NCT01217632</DOCNO>
	<brief_summary>The overall goal trial evaluate efficacy FG-3019 reversing liver fibrosis subject chronic hepatitis B infection begin antiviral therapy entecavir . This Phase 2 randomize , double-blind , placebo control study enroll subject chronic active hepatitis B infection liver fibrosis ( Ishak score ≥2 ) eligible antiviral therapy .</brief_summary>
	<brief_title>A Study FG-3019 Subjects With Liver Fibrosis Due Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Signed inform consent Age 18 75 year , inclusive HBsAg positive ≥24 week prior screen Liver fibrosis , confirm biopsy histology Willing use contraception Female subject pregnant nursing Prior antiviral therapy , exception interferon therapy &gt; 6 month prior Day 1 Severe heart failure Present hepatocellular carcinoma history cancer Severe anemia Advanced kidney disease Immunosuppressive therapy within 24 week prior screen Alcohol drug abuse within 12 month prior screen Trauma surgical procedure require hospitalization within 8 week prior Day 1 Planned elective surgery study include 9 week follow final dose study drug History allergy nucleoside analogs human , humanize , chimeric , murine monoclonal antibody Inability cooperate study personnel history noncompliance medical regimen ( i.e. , subject would expect comply poorly treatment ) Clinically significant medical psychiatric condition consider high risk participation investigational study Morbid obesity ( body mass index [ BMI ] &gt; 40 ) Inadequate IV access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Connective tissue growth factor ( CTGF )</keyword>
	<keyword>human IgG1 monoclonal antibody</keyword>
</DOC>